加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效

Clinical efficacy of modified Maimendong decoction combined with anlotinib on advanced driver gene-negative non-small cell lung cancer

目的:探究加味麦门冬汤联合安罗替尼对气阴两虚型晚期驱动基因阴性非小细胞肺癌(NSLC)的临床疗效。方法:回顾性分析接受安罗替尼治疗的气阴两虚型晚期驱动基因阴性NSLC患者的临床资料,按是否联合加味麦门冬汤治疗分为观察组(n=57)及对照组(n=55)。比较两组患者临床疗效及不良反应发生情况,观察治疗前及治疗3个疗程后两组患者中医证候积分、血清肿瘤标志物水平[癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA-21)、糖类抗原125(CA125)]、疾病相关生化指标[血管内皮生长因子(VEGF)、血小板衍生生长因子(PDGF)]、生存质量[卡氏功能状态评分(KPS)]变化,并比较治疗1年后两组患者生存情况。结果:治疗3个疗程后,观察组临床总有效率、KPS评分明显高于同期对照组(均P<0.05),血清肿瘤标志物、疾病相关生化指标水平显著低于同期对照组(均P<0.05)。治疗1年后,观察组生存率高于同期对照组(P<0.05)。两组患者不良反应比较差异无统计学意义(P>0.05)。结论:加味麦门冬汤联合安罗替尼能够改善气阴两虚型晚期驱动基因阴性NSLC患者证候,降低血清肿瘤标志物水平,抑制肿瘤细胞转移,提高患者生存质量,且不良反应较少。

Objective:To explore the clinical efficacy of modified Maimendong decoction combined with anlotinib in the treatment of advanced driver gene-negative non-small cell lung cancer(NSLC)of qi and yin deficiency.Methods:The clinical data of patients with advanced driver gene-negative NSLC of qi and yin deficiency type were retrospectively analyzed.They were divided into observation group(n=57)and control group(n=55)according to whether they were treated with Maimendong decoction or not.The clinical efficacy and occurrence of adverse reactions,TCM syndromes scores,serum tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA-21),carbohydrate antigen 125(CA125)],disease-related biochemical indicators[vascular endothelial growth factor(VEGF),platelet-derived growth factor(PDGF)]and quality of life[Karnofsky Performance Status(KPS)]before treatment and after 3 courses of treatment and survival status after 1 year of treatment were compared between both groups of patients.Results:After 3 courses of treatment,the clinical effective rate and KPS score in observation group were significantly higher than those in control group(all P<0.05),while the levels of serum tumor markers and disease-related biochemical indicators were significantly lower than those in control group(all P<0.05).The survival rate in observation group after 1 year of treatment was higher than that in control group(P<0.05).There were no significant differences in adverse reactions between the two groups(P>0.05).Conclusion:Modified Maimendong decoction combined with anlotinib can improve the syndrome of qi and yin deficiency of advanced driver gene negative NSLC patients,reduce the level of serum tumor markers,inhibit tumor cell metastasis,improve the quality of life of patients,and have fewer adverse reactions.